BMY vs CURX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BMY is the larger of the two ($126.33B market cap): the incumbent the market prices for continued execution (9.23x forward earnings, beta 0.19). CURX is the smaller challenger ($9.72M): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs CURX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | CURX | What it tells you |
|---|---|---|---|
| Market cap | $126.33B | $9.72M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Price vs 52-week range | 71% of range | 27% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.40 | 1.84 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and CURX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and CURX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and CURX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Curanex Pharmaceuticals (CURX) do?
Curanex Pharmaceuticals is a developmental-stage drug company that discovers and develops botanical drugs (medicines derived from plant material) to treat inflammatory diseases. Its lead candidate, Phyto-N, is an extract from a single plant with anti-inflammatory activity that the company says works through multiple biological targets and mechanisms. Curanex has reported validating Phyto-N in animal models across six inflammatory conditions, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with moderate-to-severe ulcerative colitis as the primary indication. The company has no approved products and therefore no product revenue; its path to making money depends entirely on advancing Phyto-N through clinical trials and ultimately to FDA approval, or on licensing or partnering the asset.
BMY vs CURX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- CURX drivers: A single asset aimed at a large market; Long human-use history as the differentiator.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For CURX, curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval.
BMY or CURX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; CURX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and CURX guides.
BMY vs CURX: the full fundamentals
BMY. At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.
CURX. For a company like Curanex, traditional valuation metrics such as price-to-earnings or revenue multiples do not apply, because there is no revenue and the losses reflect the cost of preparing for trials. What matters is the cash runway versus the cost of clinical development, the credibility of the IND and trial timeline, and how much dilution future financings may cause. A market value near $7.5 million, about 1.4 times book value, with under $3 million of cash and a burn rate several times that, signals that the market is pricing in significant financing and execution risk rather than near-term clinical value.
Headline figures (approximate, October 2026): BMY shows revenue (ttm) ~$49.2 billion (Q2 2026 up ~5.7% YoY), q2 2026 adjusted eps $2.04 vs $1.60 consensus, operating margin ~34%, net income (ttm) ~$9.3 billion; CURX shows stage Pre-clinical, pre-revenue, product revenue $0 (no approved products), net loss (ttm to jun 2026) ~$10.5M (EPS ~-$7.80, split-adjusted), cash / debt (jun 30, 2026) ~$2.9M / ~$0.3M.
The bottom line: BMY vs CURX
BMY and CURX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and CURX exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or CURX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Bristol Myers Squibb
Ask Walnut's AI anything about BMY and see how it fits what you own.
FAQ
What is the difference between BMY and CURX?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Curanex Pharmaceuticals is a developmental-stage drug company that discovers and develops botanical drugs (medicines derived from plant material) to treat inflammatory diseases. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or CURX the better stock?
+
Neither is universally better. BMY is the larger incumbent; CURX is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or CURX?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and CURX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs CURX?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. CURX: Curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval. Botanical drugs face the same FDA evidentiary bar as other drugs, and most early candidates never reach the market. Cash of roughly $2.9 million at mid-2026 is small next to a trailing net loss of about $10.5 million, the company has carried a going-concern style of disclosure typical of early biotechs, and it may need to raise capital on dilutive terms soon. The stock is thinly traded, has fallen about 66% over the past year, and already needed a 1-for-20 reverse split in August 2026 after receiving a Nasdaq deficiency notice, so continued weakness could bring renewed listing pressure. Holders face extreme volatility and the possibility of a total loss. Figures are approximate and drawn from public filings and market data as of October 2026.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or CURX; figures are approximate and dated (as of November 2026). Verify current data before investing.